Median duration and factors that influence the duration of symptom resolution in COVID‐19 patients in Ethiopia: A follow‐up study involving symptomatic cases

BACKGROUND: Understanding the clinical features of COVID‐19 and duration for resolution of symptoms is crucial for isolation of patients and tailoring public health messaging, interventions and policy. Therefore, this study aims to assess the median duration of COVID‐19 signs and symptoms’ resolution and explore its predictors among symptomatic COVID‐19 patients in Ethiopia. METHODS: A hospital‐based prospective cohort study involving 124 COVID‐19 cases was conducted at Eka Kotebe General Hospital, COVID‐19 Isolation and Treatment Center. The study participants were all symptomatic COVID‐19 adult patients admitted to the hospital from 18 March to 20 August 2020. Physicians at the centre recorded the data using a log sheet. Cox proportional‐hazards regression model was conducted. Statistical significance was defined at P < 0.05. RESULTS: A total of 124 symptomatic COVID‐19 patients with a mean age of 42 years (±17) were involved in the study. The median duration of symptom resolution of COVID‐19 was seven days with a minimum of two and a maximum of sixty‐eight days. Sex and body mass index (BMI) were statistically significant predictors of the symptom resolution. The hazard of having delayed sign or symptom resolution in males was 55% higher than in females (P = 0.039; CI: 0.22–0.96) and the hazard of delayed sign or symptom resolution in those with BMI ≥ 25 kg/m(2) was 35% higher than in those with BMI < 25 kg/m(2) (P = 0.041; CI: 0.44–0.98]). CONCLUSIONS: The median duration of COVID‐19 symptom resolution was seven days. Being male and/or having a BMI ≥ 25 kg/m(2) were predictors of a delayed sign or symptom resolution time. Therefore, it is important to consider proportion of males and those with BMI ≥ 25 kg/m(2) when preparing isolation and treatment centres. Males and individuals with BMI ≥ 25 kg/m(2) shall also be given priority when shielding from the COVID‐19.